2020   Acquired JHK Biopharma's shares(25%) & proceeding extension work for TDDS factory

2019   Divestment of C-TRI's shares(1,452,598 shares)
2019   FPI of Liporaxel's Chinese phase 3 trial for breast cancer was managed
2019   Acquired 'ISO37001' certificate, Anti-bribery management system
2019   Received Excellence Award of business ethics in Free Trade Commission
2019   Established a joint venture with JHK BIO in China
2019   FPI of Liporaxel's Chinese phase 3 trial for breast cancer was managed.
2019   Investment cooperation with Haihe Bio Pharma in China
2019   Completed DHP1401 Phase 2 clinical trial in Korea
2018   Approved for phase 3 clinical trial of Liporaxel® for stomach cancer and breast cancer in China FDA
2018   Liporaxel® New Drug Development Award, Excellence Award
2017   Approved for phase 2 clinical trial of Liporaxel® for breast cancer in US FDA
2017   Germany/S&V and BSC added as affiliates
2017   Technology export of Liporaxel® to China
2016   Approval of Liporaxel Sol.(DHP107) from MFDS
2016   Hyangnam factory, assets transfer (contribution in kind) to Redox-bio Co., Ltd.(affiliate
2016   Purchase of Bangbae-dong Company Building (Seocho-gu Nambusunhwan-ro 2145)
2016   DHP1401(Natural drug for Dementia) selected as a development project of the Advanced medical technology by MoHW
2015   DHP107 dedicated 3rd Factory construction in Hoengseong
2015   Success of DHP107 phase III clinical tria
2015   Won the Government prize of $5 Million Export Tower Award on 52th Trading day
2015   C-Tri Pharmaceutical Co. (sister company) KOSDAQ registration selling and buying begin
2015   Approval of DHP1401 (natural drug for Dementia) phase II clinical trial
2015   Re-selection of Innovative Pharmaceutical Company by MoHW
2015   Change of CEO (Byung-Tae, No & Eun-Seok, Kim)
2015   Reauthorization of DHP107 (oral anti-cancer drug) as New Excellent Technology(NET) by MoHW
2014   Change of CEO (Han-Koo, Lee & Soo-Ji, Kim)
2013   Change of CEO (Han-Koo, Lee)
2013   Takeover Redox bio corp.
2013   DHP 107 was selected as MOTIE (Ministry of Trade, Industry & Energy) research
2013   Approved protocol for Clinical trial phase III of DHP 107 (MFDS - Ministry of Food and Drug Safety)
2012   Completed Clinical trial phaseⅡ of DHP107
2012   Certified as “Innovative Pharmaceutical Corporation”
2011   Approved NET(New Excellent Technology) for DHP 107
2011   Started to produce plaster,cataplasma, patch in Hoengseong factory
2011   Completed Pangyo laboratory
2011   Changed CI(corporate identity)
2010   Awarded “Three Million Dollar Export Award”
2010   Approved protocol for Clinical trial phase II of DHP 107 oral anticancer by KFDA

2009   Completed cGMP factory
2008   Change of CEO (Han-Koo, Lee & Byung-Tae, No)
2008   Approved protocol for Clinical trial phase I of DHP 107 oral anticancer by KFDA
2007   Takeover Specialized-med
2007   Takeover Deache Parma
2007   Finish the animal toxicology test for DHP 107 oral anticancer (US Covance)
2006   Combined with DS&G
2006   Designated as Gangwon - Promising Small and Medium Company
2005   Designated as New technology venture company by Gangwon
2005   Starting the business (Communication sales & Electronic commerce, etc)
2004   Takeover the C-TRI as subsidiary company
2004   Relocated the Head office and factory (Gangwon-do)
2004   The completion of the new company building in Dae jeon city
2003   Designated as New technology venture company by Gyeonggi
2003   Registered in Korea Securities Dealers Association
2002   List on the KOSDAQ
2002   Purchsed the New factory(82,645 m2) and facilities from multinational company
2001   Designated as "a venture company" by Small & Medium Business Administration
2000   Designated as Gyeonggi - Promising Small and Medium Company
2000   Awarded "One Million Dollar Export Award"

1999   Moved into the current Head office Locations : Dae Hwa Bldg., 2038, Nambusunhwan-ro, Gwanak-gu, Seoul, Republic of KOREA
1997   Succeeded in self-developing of Home Pregnancy Test Kit, 'I CAN TEST-HCG'
1996   Acquired the permission of the export products from the Vietnam Government
1994   Beginning to export finished products to overseas
1993   Designated as Korean GMP approval for the Plant by Korean Ministry of Health. Established the Central Research Institute of DAE HWA Pharm
1992   Established the Plant for Korean GMP facility in Shihwa-Industrial Complex at Jeongwang-dong, Siheung-si, Gyeonggi-do

1989   Get approval of trade business
1988   The building of our company moved to Bangbae-dong, Seocho-gu, Seoul
1987   Designated as 'A Promising Medium-sized Enterprise'
1986   Resigned as President Ki-Yong, Kim. Assumed office as President Soo-Ji, Kim and Woon-Jang, Kim
1984   DAE HWA Pharmaceutical Co., Ltd. founded by President Ki-Yong, Kim in 34, Changmi-dong, Koonsan-si, Jeollabuk-do, Korea